<DOC>
	<DOCNO>NCT02212561</DOCNO>
	<brief_summary>The purpose study test safety selinexor ( KPT-330 ) find high dose selinexor ( KPT-330 ) give safely combine two chemotherapy drug ( fludarabine cytarabine ) . This study do two part : Phase I Phase II . The goal Phase I find high tolerable dose selinexor ( KPT-330 ) give patient leukemia MDS , combine fludarabine cytarabine . The goal subsequent Phase II portion study ( insert NCT ID SELHEM-2 ) give high dose selinexor ( KPT-330 ) combination fludarabine/cytarabine find Phase I safe child leukemia MDS . The investigator examine effect combination treatment . PRIMARY OBJECTIVE : - Determine tolerable combination selinexor , fludarabine , cytarabine pediatric patient relapse refractory hematologic malignancy include acute myeloid leukemia ( AML ) , acute lymphoblastic leukemia ( ALL ) , mixed phenotype acute leukemia ( MPAL ) myelodysplastic syndrome ( MDS ) . SECONDARY OBJECTIVES : - To characterize pharmacokinetics selinexor , administered tablet form , first dose steady-state , well combination fludarabine cytarabine - To estimate overall response rate selinexor give fludarabine cytarabine patient relapse refractory hematologic malignancy</brief_summary>
	<brief_title>Selinexor With Fludarabine Cytarabine Treatment Refractory Relapsed Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description>Phase I characterize dose-limiting toxicity ( DLTs ) determine maximum tolerate dose ( MTD ) recommend phase II dose selinexor give combination fludarabine cytarabine . Selinexor give twice weekly ( day 1 3 ) escalate de-escalated base tolerability . The rolling-6 design use study . Only cycle 1 therapy use evaluate DLT . Two six participant concurrently enrol onto dose level , dependent 1 ) number participant enrol current dose level , 2 ) number participant experience DLT current dose level , 3 ) number participant enter tolerability data pending current dose level . Accrual suspend cohort six enrol study endpoint meet . Once recommended Phase II dose determine , additional patient enrol , necessary , least 6 subject treat recommend Phase II dose determine MTD . After MTD determine , 12 additional patient treat dose level evaluation tolerability response .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Participants must diagnosis AML , MDS , ALL MPAL must disease relapsed refractory chemotherapy , relapse hematopoietic stem cell transplantation ( HSCT ) Refractory disease define persistent disease least two course induction chemotherapy . Patients AML , MPAL MDS eligible first subsequent relapse , whereas patient ALL eligible second subsequent relapse relapse refractory salvage chemotherapy . Patients AML ALL must ≥ 5 % leukemic blast bone marrow increase level MRD bone marrow assess flow cytometry . If adequate bone marrow sample obtain , patient may enrol unequivocal evidence leukemia peripheral blood . Adequate organ function define follow : Direct bilirubin ≤ 1.5 x institutional upper limit normal ( IULN ) AST ( SGOT ) /ALT ( SGPT ) &lt; 3 x IULN Creatinine within normal institutional limit age Prothrombin time ( PT ) partial thromboplastin ( PTT ) ≤ 1.5 x IULN . Age criterion : Patients treat collaborate site current St. Jude patient therapy within 3 year completion therapy must ≤ 24 year old . All St. Jude patient must &lt; 21 year old . Patients must able swallow tablet . Performance status : Lansky ≥ 50 patient ≤ 16 year old Karnofsky ≥ 50 % patient &gt; 16 year old . Patients must fully recover acute effect prior therapy . For patient receive prior HSCT , evidence GVHD great 60 day must elapse since HSCT . History cerebellar toxicity cerebellar neurological finding exam . Must pregnant breastfeeding . Female patient childbearing potential must agree use dual method contraception negative serum pregnancy test screening , male patient must use effective barrier method contraception sexually active female childbearing potential . Acceptable method contraception condom contraceptive foam , oral , implantable injectable contraceptive , contraceptive patch , intrauterine device , diaphragm spermicidal gel , sexual partner surgically sterilize postmenopausal . For male female patient , effective method contraception must use throughout study three month follow last dose . Patients Down syndrome , acute promyelocytic leukemia , juvenile myelomonocytic leukemia , Fanconi anemia , Kostmann syndrome , Shwachman syndrome , bone marrow failure syndromes eligible . Use investigational agent , exception gemtuzumab ozogamicin , within 30 day . Any significant concurrent disease , illness , psychiatric disorder would compromise patient safety compliance , study participation , follow , interpretation study research . Unstable cardiovascular function : symptomatic ischemia congestive heart failure NYHA Class &gt; 3 myocardial infarction ( MI ) within 3 month Uncontrolled infection require parenteral antibiotic , antiviral , antifungal within one week prior first dose . Infections control concurrent antimicrobial agent acceptable , antimicrobial prophylaxis per institutional guideline acceptable . Known human immunodeficiency virus ( HIV ) infection ( prestudy testing require ) . Patients malabsorption syndrome , disease significantly affect gastrointestinal function . Prior treatment selinexor .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>